Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2Phase 1 1

Status

Completed 2Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Breast Neoplasms 7244Neoplasms 4539Prostatic Neoplasms 3489Colorectal Neoplasms 2940Carcinoma, Non-Small-Cell Lung 2831Lung Neoplasms 2547Leukemia, Myeloid, Acute 1982Pancreatic Neoplasms 1874Multiple Myeloma 1811Carcinoma, Hepatocellular 1733Neoplasm Metastasis 1585Stomach Neoplasms 1502Lymphoma 1457Precursor Cell Lymphoblastic Leukemia-Lymphoma 1435Head and Neck Neoplasms 1435Brain Neoplasms 1373Melanoma 1348Ovarian Neoplasms 1342Leukemia 1303Rectal Neoplasms 1270Recurrence 1255Colonic Neoplasms 1204Glioblastoma 1138Uterine Cervical Neoplasms 1096Lymphoma, Non-Hodgkin 1066Leukemia, Lymphocytic, Chronic, B-Cell 989Esophageal Neoplasms 965Lymphoma, Follicular 936Lymphoma, Large B-Cell, Diffuse 932Squamous Cell Carcinoma of Head and Neck 921

Interventions

zirconium-89-trastuzumab 1STA 9090 1Positron-Emission Tomography 1Pemetrexed 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Interventional × Esophagogastric Cancer × Clear all
NCT03133650 2026-04-16

A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
12 enrolled
Gastrointestinal

Esophagogastric Cancer

NCT05796102 2026-03-05

PET-MRI

University Health Network, Toronto

Phase NA Recruiting
15 enrolled
Gastrointestinal

Esophagogastric Cancer

NCT02023996 2024-12-10

PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer

Memorial Sloan Kettering Cancer Center

Phase NA Completed
42 enrolled 11 charts
Gastrointestinal

Esophagogastric Cancer

NCT01167114 2023-11-02

STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer

Massachusetts General Hospital

Phase 2 Completed
28 enrolled
Gastrointestinal

Esophagogastric Cancer

NCT02296671 2016-03-08

Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers

Washington University School of Medicine

Phase 2 Withdrawn
Gastrointestinal

Esophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡